AUS
NZ
UK
CA
USA
IND
Elevance Health, Inc., the Indianapolis-based managed care and health benefits provider, released its second quarter 2026 financial results on July 15, 2026. The company filed a current report with regulators, signed by Chief Governance Officer and Corporate Secretary Kathleen S. Kiefer, detailing its financial performance for the quarter ended June 30, 2026. While the filing references a press release as Exhibit 99.1, the detailed financial data was not included in the report text itself. Investors in the managed care industry will be closely monitoring these quarterly results as Elevance Health navigates the challenging healthcare landscape in 2026.
Key Highlights
- Trading on NYSE under ticker ELV (also tracked via NASDAQ profile)
- Second quarter 2026 results announced via July 15, 2026 press release
- Detailed revenue, earnings, membership, and guidance figures are provided exclusively in Exhibit 99.1
- Market focus on operating metrics, medical cost ratios, and sector outlook commentary in the accompanying release
Elevance Health Files Q2 2026 Earnings Disclosure on July 15, 2026
On July 15, 2026, Elevance Health, Inc. officially disclosed its financial results for the second quarter ending June 30, 2026, through a regulatory current report. The filing, submitted under Item 2.02 for Results of Operations and Financial Condition, confirms the company’s quarterly performance during the April to June 2026 period.
Signed by Kathleen S. Kiefer, Chief Governance Officer and Corporate Secretary, the report identifies Elevance Health’s principal office at 220 Virginia Avenue, Indianapolis, Indiana 46204. The company’s common stock, with a par value of $0.01 per share, trades on the New York Stock Exchange under the symbol ELV.
Comprehensive Financial Details Available in Press Release Exhibit 99.1
The full financial results for Q2 2026 are contained in Exhibit 99.1, the press release dated July 15, 2026, which accompanies the filing. The current report itself does not disclose specific financial metrics such as total revenue, net income, earnings per share, medical loss ratio, or membership numbers. Investors must review Exhibit 99.1 for detailed operational and financial information.
This approach aligns with industry standards where quarterly earnings releases are furnished as exhibits to current reports rather than embedded within the filing text. The press release is incorporated by reference, making both documents collectively the official quarterly disclosure submitted on July 15, 2026.
Significance of Item 2.02 Filing for Investors
Filing under Item 2.02 signals that the information relates directly to Elevance Health’s financial results and operational condition for Q2 2026, rather than other corporate events. The filing includes a legal disclaimer that the information provided is "furnished" and not "filed" under Section 18 of the Securities Exchange Act of 1934, limiting liability but not diminishing its importance for investors and analysts.
Elevance Health’s Market Role and Corporate Overview in 2026
Elevance Health, Inc. ranks among the largest U.S. health insurance and managed care companies, operating across commercial, Medicare, and Medicaid segments. Its Carelon subsidiary provides health services, and the company’s extensive membership base and multi-state presence make its quarterly results a key indicator for the U.S. managed care sector.
Formerly known as Anthem, Inc. until its 2022 rebranding, Elevance Health reflects a broader health company identity beyond insurance. Headquartered in Indianapolis, Indiana, the company employs a substantial workforce. In 2026, the managed care industry faces scrutiny over medical cost trends, utilization, and regulatory changes, heightening the significance of Elevance Health’s quarterly disclosures.
Regulatory Context of the July 15 Filing
The Item 2.02 current report communicates material financial information to the market and is typically accompanied by earnings calls or investor presentations, though this filing does not specify if such events occurred. The filing confirms no related communications under Rules 425, 14a-12, 14d-2(b), or 13e-4(c), indicating the report is a standalone quarterly earnings announcement unrelated to mergers, acquisitions, or proxy solicitations.
Authorized Signatory and Governance Details
Kathleen S. Kiefer signed the filing as Chief Governance Officer and Corporate Secretary, consistent with standard corporate governance practices for routine regulatory disclosures. The filing does not indicate any changes in leadership, board composition, or governance structure. The effective date and earliest event date of the filing is July 15, 2026, coinciding with the press release date.
Stock Listing and Registration Information
Elevance Health’s common stock is registered under Section 12(b) of the Securities Act and trades on the NYSE as ELV with a $0.01 par value per share. The company’s Commission File Number is 001-16751, and its IRS Employer Identification Number is 35-2145715. The filing confirms Elevance Health is not an emerging growth company, subjecting it to full financial reporting requirements applicable to large accelerated filers.
Details Not Included in the Report Body
The current report excludes specific financial figures such as revenue, operating income, net income, adjusted earnings per share, total membership, medical loss ratio, or fiscal year 2026 guidance. No mention is made of special charges, restructuring, litigation settlements, or extraordinary items in the report body. Investors must consult Exhibit 99.1 for comprehensive financial disclosures and any sector-specific developments impacting the quarter.
Market Impact and Investor Focus Areas
The immediate effect on Elevance Health’s stock price following the July 15 announcement was not publicly available. Quarterly earnings from major managed care firms like Elevance Health often influence market sentiment based on how results compare to analyst expectations and guidance updates. Key investor interests include government program performance, commercial membership trends, Carelon segment profitability, and regulatory and reimbursement dynamics under Medicare Advantage and Medicaid contracts.
These factors remain critical for institutional investors, analysts, and healthcare policymakers monitoring the managed care industry throughout 2026.
